Skip to main content
Search
Search
Search
Search
Main navigation
About pCPA
Who We Are
Governance
Strategic Plan
Reports
What's New at the pCPA
FAQs
Careers
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
pCPA Temporary Access Process (pTAP)
Contact Us
EN
FR
Alecensaro (alectinib)
pCPA File Number:
21039
Negotiation Status:
Concluded with an LOI
Indication(s):
Locally advanced or metastatic non-small cell lung cancer
Sponsor/Manufacturer:
Hoffmann-La Roche
CADTH Project Number:
pCODR 10114
pCPA Engagement Letter Issued:
2018-09-07
Negotiation Process Concluded:
2018-12-11